What do we know from the sub-analyses of the ODYSSEY Outcomes Trial that looked at patients with LDL-C levels below 50 mg/dL? Which of these, based on baseline LDL-C levels, derived disproportionate mortality reduction benefit from alirocumab?

Name: What do we know from the sub-analyses of the ODYSSEY Outcomes Trial that looked at patients with LDL-C levels below 50 mg/dL? Which of these, based on baseline LDL-C levels, derived disproportionate mortality reduction benefit from alirocumab?
Uploaded: 2019-03-05T00:00:00+00:00

CLICK HERE FOR CME CREDIT

Created by

Presenter

Andreas Zeiher, MD

Chairman of Medicine
Department of Cardiology, Angiology, and Nephrology
J. W. Goethe University
Frankfurt, Germany